Cancers that arise from astrocytes in the adult CNS present as either anaplastic astrocytomas (AAs) or as more aggressive glioblastomas multiforme (GBMs). GBMs either form de novo or progress from AAs. We proposed to examine the molecular genetic relationship between these CNS tumors by conducting a genome-wide allelic imbalance analysis that included 70 loci on examples of AA and GBM. We found signi cant loss of heterozygosity (LOH) at 13 discrete chromosomal loci in both AAs and GBMs. Loss was signi cant in both AAs and GBMs at 9 of these loci. AAs show the highest rates of LOH at chromosomes 1p, 4q, 6p, 9p, 11p, 11q, 13q, 14q, 15p, 17p, 17q, and  19q. GBMs showed the greatest losses at 1p, 6q, 8p, 9p,  10p, 10q, 11p, 13q, 17p, 17q, 18p, 18q, and 19q . GBMs also demonstrated signi cant ampli cation at the epidermal growth factor receptor locus (7p12). These data suggest that there are three classes of loci involved in glioma evolution. First are loci that are likely involved in early events in the evolution of both AAs and GBMs. The second class consists of AA-speci c loci, typi ed by higher LOH frequency than observed in GBMs (4q, 6p, 17p, 17q, 19q) . The third class consists of GBM-speci c loci (6q, 8p, 10, 18q). Damage at these loci may either lead to de novo GBMs or permit existing AAs to progress to GBMs. Glioma-related LOH pro les may have prognostic implications that could lead to better diagnosis and treatment of brain cancer patients. Neuro-Oncology 1, 169-176, 1999 (Posted to Neuro-Oncology [serial online], Doc. 98-28, June 16, 1999 
A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution 1 Cytogenetic and LOH studies of malignant astrocytomas have shown that chromosome loss is more widespread in GBM than in AA (Fults 1996; von Deimling et al., 1995) . These observations support the hypothesis that inactivation of multiple tumor suppressor genes located on different chromosomes is a driving force in astrocytoma progression. Allelic deletions on 9p, 11p, 13q, and 19q are equally prevalent in both AA and GBM, suggesting that inactivation of tumor suppressor genes located in these chromosomal regions precedes the formation of malignant astrocytoma. By contrast, loss on chromosome 10 occurs much more frequently in GBM than in AA, suggesting that loss of tumor suppressor genes on chromosome 10 mediates the transition from AA to end-stage GBM. GBMs have also been observed to develop rapidly, seemingly without clinical or histopathologic precursors, particularly in older patients . This observation, and the fact that individual GBM cases vary with regard to the chromosome sites showing deletions, suggests that not all GBMs arise by progressing through the AA stage. Some may arise by alternative pathways that should be recognizable by a different set of altered genes than are observed in AA.
Previous genetic studies of malignant astrocytomas have identi ed regions of oncogene activation (most commonly gene ampli cation of EGFR at 7p12) (Bello et al., 1994; Bijlsma et al., 1994; Fischer et al., 1994; Leenstra et al., 1994; Muleris et al., 1994; Schrock et al., 1996; von Deimling et al., 1994) as well as tumor suppressor gene inactivation as de ned by LOH. LOH has been reported in gliomas at 9p (MTS1/CDKN2A and MTS2/CDKN2B), 13q (RB), Neuro-Oncology n JU LY 19 9 9 170 E.C. Wooten et al.: LOH in anaplastic astrocytoma and glioblastoma multiforme 11p, 17p (p53/TP53), and 19q (Fults and Pedone, 1993; Collins, 1995; von Deimling et al., 1994; Schlegel et al., 1996; Debelenko et al., 1997; Kimura et al., 1996; Fults et al., 1992b; Thiel et al., 1992; Li et al., 1997) . GBM (and other severe cancers) have been associated with the MMAC/PTEN gene on 10q (Steck et al., 1995; . An important question remains: Are there as yet uncharacterized LOH events that could serve as the signposts for additional tumor suppressor genes involved in the genesis or progression of malignant astrocytomas? Polymerase chain reaction-based microsatellite markers that detect polymorphisms within the abundant short tandem repeats throughout the human genome have made it possible to construct high-resolution genetic linkage maps of human chromosomes. The resolution of these maps can approach one centimorgan (Gyapay et al., 1994; Murray et al., 1994) . The high polymorphism information content of microsatellite markers, as compared with earlier restriction fragment length polymorphism markers, results in a signi cantly greater sensitivity when attempting to detect allelic imbalance in patient tumor DNA samples. We carried out a comprehensive LOH analysis of 45 malignant astrocytoma patients using highly informative microsatellite markers for 70 distinct autosomal loci. We found several previously unreported allelic deletions. These suggest potential sites for novel tumor suppressor genes.
Methods

DNA Samples
DNA was prepared either from lymphoblastoid cell lines or from resected brain tumors. Histopathologic grading was based on the classi cation scheme of Burger et al. (1985) . Nineteen pairs of samples were from patients with AAs, and 26 pairs of samples came from patients with GBMs for a total of 45 sample pairs. Tumor resection was precise enough to ensure that 75% of the cellularity of each sample was derived from the targeted tissue. Cellular enrichment was about 90% in most samples. Tumor and lymphoblastoid cell line DNA samples were prepared as previously described (Fults et al., 1990) .
Polymerase Chain Reaction, Gels, and Quantitation of LOH
Samples were independently evaluated for LOH at each of the polymorphic markers. The antisense primer was 5'-radiolabeled in a standard polynucleotide kinase reaction by 3,000 Ci/mmol [g 32 P]ATP at a molar ratio of 18:1 ([g 32 P]ATP:Primer) (Steck et al., 1997) . DNA template (100 ng) was subjected to 30 cycles of polymerase chain reaction (denaturing at 94°C for 30 s, annealing at approximately 55°C for 1 min, and extension at 72°C for 1 min) carried out in a 15-m l reaction in a 96-well thermocycler. Ampli ed DNA was diluted 1:1 with stop solution (97% formamide, 1% EDTA, 0.1% bromophenol blue, and 0.1% xylene cyanol) and denatured at 85°C for 2 min. Denatured DNA (3 ml from each sample) was loaded onto a 7% denaturing polyacrylamide (19:1 acrylamide/bis-acrylamide) gel containing 32% formamide and 34% urea and was fractionated by gel electrophoresis for approximately 2.5 h at 60 W. Gels were transferred to lter paper, covered with plastic wrap, equilibrated with 10% methanol/10% acetic acid solution, and dried. Dried gels were exposed to X-ray lm without an intensifying screen (usually 16 h).
The markers used and their approximate chromosomal locations are shown in Table 1 . Details concerning marker polymorphisms and sequence can be obtained from the Genome Database (GDB TM ), formerly at The Johns Hopkins University, now at the Hospital for Sick Children in Toronto (Henson et al., 1994) . The GDB World Wide Web URL is http://gdbwww.gdb.org/. Genetically informative samples showed two distinguishable alleles. The intensity ratio of the two allelic bands of DNA from normal tissue relative to that from gliomas in the same case was obtained from digitized data collected with a phosphorimager and analyzed with the Molecular Dynamics ImageQuant (Molecular Dynamics, Sunnyvale, Calif.) software package. A conservative ratio of 1.5 was used to de ne LOH in this study. Our 75% target cell enrichment was adequate to meet or exceed this ratio in cases with pervasive LOH. Experiments were repeated three times to validate the stability of the LOH phenotype. Microsatellite instability was not a major nding for these allelotyping studies. A total of two AA samples (11%, 2 events each) and only 1 GBM sample (4%, 3 events) showed multiple microsatellite instability events, and such cases were excluded from further analysis. Quantitation of EGFR ampli cation was accomplished by multiplexing EGFR primers with primers from chromosomal loci known to show little or no LOH and of a suf ciently different product size to allow for suf cient resolution of both products.
Statistical Analysis
Empirical observations lead us to suspect a 20% LOH rate at any given locus represented a signi cant, nonbackground loss. To determine if there was statistical signi cance to this observation, we used Fisher's exact test (Sokal and Rohlf, 1981 ) and compared loss rates between frequently and infrequently lost loci in both AA and GBM DNA sets. These analyses showed losses of 20% and above to be highly signi cant. 
Results
These studies investigated patterns of LOH in 19 patients with AA and 26 patients with GBM by using 70 autosomal genetic markers spaced at an average of 50 centimorgans across the 22 autosomes. Table 1 indicates the markers tested, approximate genetic locations, and observed LOH (expressed as a percentage of informative patients). Fig. 1 shows representative autoradiographic data. Statistical analysis between the loci showing maximum and minimum genetic changes by chromosome arm was performed for both AAs and GBMs. The signi cance of loss rates was
Neuro-Oncology n JU LY 19 9 9 172 E.C. Wooten et al.: LOH in anaplastic astrocytoma and glioblastoma multiforme determined by Fisher's exact test (two-sided). The background rate of loss was determined to be <20% at all loci examined for this study (Table 2) . Therefore, all losses of 20% and above are highly signi cant (P = 0.0029). The chromosome arms exhibiting nonrandom LOH at signi cant frequencies ( 20%) are listed in Table 1 in boldface type. Approximate megabase location is included for every locus, and chromosomal band location is also given (where possible). Locus band and megabase location is available from the Genome Database (GDB) (Henson et al., 1994) at the World Wide Web URL http://gdbwww.gdb.org/. Approximate chromosomal sizes are used as defined by Newton E. Morton (1991) . Fig. 2 summarizes the peak observed LOH by chromosome arm as AA-and GBM-speci c histograms. Ampli cation of the EGFR region at 7p12 was observed in 12% of AA samples and 38% of GBMs.
We compared LOH test results in the patient groups with AA and GBM for loci showing an LOH frequency 20% (Table 2) . When compared in this way, three distinct groups of chromosomal loci became apparent. In the rst group-D9S157 (9p), D11S922 (11p), D13S137 (13q), D17S731 (17q), and D19S601 (19q)-the frequency of LOH was signi cantly above background in patients with AA and patients with GBM. In the second group-D6S471 (6q), D8S264 (8p), D10S249 (10p), D10S196 (10q), and D18S46 (18q)-LOH was signicant only in patients with GBM. In the third group-D1S243 (1p), D1S255 (1q), D4S407 (4q), D6S344 (6p), D11S988 (11q), D14S62 (14q), TP53 (17p), and D19S601 (19q)-the frequency of LOH was signi cantly higher in patients with AA.
To identify any pairs of concomitantly lost markers, we examined CALR at pairs of markers by cancer type (Table 3) . Three primer pairs-D4S407-D17S731, D6S344-D13S137 (in AAs), and D8S264-D11S922 (in GBMs)-showed evidence of nonrandom CALR, but became nonsigni cant (although borderline) when corrected for multiple testing. These observations, although nonsigni cant, are strengthened by the fact that intrachromosomal pairs D11S922-D11S988 and PS31(P53)-D17S731 showed CALR of a similar magnitude.
Discussion
Data from our comprehensive LOH analysis of the AA and GBM panels support previous ndings in the eld and identify several potential chromosomal locations for novel tumor suppressor genes. Overall, the present study revealed higher LOH frequencies than reported previously in an allelotype analysis of malignant astrocytoma that used restriction fragment length polymorphism markers (Fults et al., 1990) .
We report ampli cation at the EGFR locus. Our ndings are in agreement with previous reports of high levels of amplification (38%) in GBMs coupled with lower ampli cation levels (12%) in AAs. Several groups Reifenberger et al., 1996; von Deimling et al., 1992a ) have attempted to classify gliomas based on EGFR ampli cation, LOH status at 17p (p53), and LOH at chromosome 10. We report increasing EGFR amplication with increased LOH at chromosome 10 in GBMs, which correlates well with previous studies. AAs show AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; NS, not signi cant; EGFR, epidermal growth factor receptor.
The loci listed were those with >20% allele loss rates either in AA or GBM. The signi cance of allele loss rates was determined by Fisher's exact test (two-sided). Each test examined whether the observed allele loss rate at a given locus differed from the empirical background allele loss rate <20%. In fact, the background rate was computed to be the average of the allele loss rates <20% at all loci examined for this study, excluding the above 17 markers.
*Signi cant after correction for multiple testing (P = 0.05/17 = 0.0029).
lower losses on chromosome 10 and low ampli cation of EGFR, coupled with high losses at 17p, again in agreement with previous studies.
As expected, we found high frequency LOH on chromosome arms containing tumor suppressor genes with known involvement in astrocytomas. These genes include MTS1/CDKN2A and MTS2/CDKN2B (9p), PTEN/MMAC1 (10q), DMBT1 (10q), RB (13q), and TP53 (17p) (Frankel et al., 1992 , Fults et al., 1992a , Henson et al., 1994 , Kamb et al., 1994 , Jen et al., 1994 , Li et al., 1997 , Steck et al., 1997 .
Additionally, we found signi cant LOH frequencies at loci (6p, 10p, 11p, 14q, 17q, and 19q) where allelic deletions were reported previously in human gliomas, but where the putative tumor suppressor gene has not yet been identi ed (Fults et al., 1990 (Fults et al., , 1992b Liang et al., 1994; von Deimling et al., 1992b) . Several markers yielded novel observations. Marker D1S255 showed approximately 24% LOH in both AAs and GBMs. LOH on 1p has not been reported in gliomas at these levels.
Two markers showed high losses in GBMs but not in AAs. Marker D6S471 on 6q showed 33% LOH and marker D18S46 showed 24% LOH in GBMs. This data suggests that losses of tumor suppressor genes on 6q and 18q may be involved in the formation of GBMs. The fact that LOH at these two loci was 10% or less in the AA series suggests that these putative genes, like the previously described genes on chromosome 10, are terminal genetic events associated with end-stage GBM.
In several instances we found high rates of LOH in AAs coupled with lower LOH rates in GBMs, suggesting a speci c involvement of these regions in the development of astrocytomas. Markers D4S407 (4q) and D14S62 (14q) showed higher LOH rates in AAs than in GBMs. This pattern of LOH may have important ramifications with regard to the controversy surrounding the genesis of AAs. Similar observations have been previously reported for chromosomes 17p (p53) and 19q (Campomenosi et al., 1996; von Deimling et al., 1992b) .
Clinically, gliomas present in two ways. GBMs often arise de novo, without apparent progression from less malignant precursors, particularly in elderly patients. In younger patients, the more frequent observation is that of GBMs progressing from less malignant tumor phenotypes by stepwise progression through increasingly malignant tumor stages, often in spite of treatment. These observations have led to two models for the progression of malignant gliomas. One model holds that a series of discrete losses to speci c tumor suppressors or gains at oncogenic loci leads through a pathway beginning with a normal cell and progressing through a serial evolution of increasingly malignant phenotypes, which ultimately results in GBM (von Deimling et al., 1995) . The rapid growth of GBMs as compared with astrocytomas could explain the observations of seemingly spontaneous GBMs. One could imagine a subclinical astrocytoma that progresses to a rapid GBM tumor, causing the histopathologic evidence of the preceding astrocytoma to be unclear or otherwise obfuscated. The second model maintains that AAs and GBMs arise from a lesionspeci c pattern of genetic damage. The observation of what appears to be tumor progression in a patient would actually be the result of the two forms arising from independent clones of transformed cells, each tumor foci having followed its own, presumably unique, pathway.
Analysis of our data suggests that these two clinical models are not mutually exclusive and that there are three types of loci involved in glioma evolution. First are loci that are probably involved in early events of the evolution of AAs or GBM, typi ed by signi cant rates of LOH in both types of lesions (7p ampli cation, 9p, 13q, 11p, and 17q). Suppressor genes at these sites are probably involved in both AAs and GBMs, and their inactivation during the progression of the tumor most likely precedes the AA stage. The second class consists of loci that appear to be AA-speci c, typi ed by patterns where LOH frequency is significantly higher in AAs than in GBMs (1p, 1q, 4q, 6p, 11q, 14q, 17p, and 19q) . The low levels of loss at these loci in GBMs may indicate that our GBM cases comprised a mixed population of tumors. Some may have progressed from less malignant astrocytoma stages, while others may have arisen by the de novo pathway. Alternatively, loss of these AA-speci c loci may de ne a subset of AAs that do not progress to the GBM stage, or do so rarely. The third class of loci are those that appear to be GBM-speci c. These are typi ed by signicant rates of LOH in GBMs but not in AAs (6q, 8p, 10, and 18q). Genetic damage at these loci could either lead to de novo GBMs or permit existing AAs from the rst two categories to progress into GBMs. Some investigators have tried to use GBM-speci c loci to subclassify these two types of GBMs (von Deimling et al., 1993) .
Using analysis of CALR, we hoped to discern any inter-relationships between pairs of loci and apparent predisposition to AAs, GBMs, or both. While several loci were found to be concordantly lost, these results become nonsigni cant when corrected for multiple testing (Table  3 ). These ndings gain importance when taken together with the CALR rates between loci on the same chromosome (chromosomes 11 and 17). Although these rates are not biologically signi cant, they serve as evidence that our Neuro-Oncology n JU LY 19 9 9 174 E.C. Wooten et al.: LOH in anaplastic astrocytoma and glioblastoma multiforme methodology is sound and raise the possibility that the interchromosomal pairs (D4S407-D17S731 and D6S344-D13S137) that are lost at similar rates could prove signicant with a larger pool of samples from which to draw. Likewise, other primer pairs could emerge as signi cant targets for CALR with a larger pool of tested loci. Our observations are consistent with the notion of an interrelated but potentially independent genetic evolution of gliomas. The widespread, nonrandom chromosome loss we observed in malignant astrocytomas indicates that the number of tumor suppressor genes involved in human gliomas exceeds that currently known. The novel chromosome deletion sites we report here may serve as targets for higher resolution deletion mapping studies and future positional cloning projects to identify novel tumor suppressor genes. These genes may serve as targets for future treatments for patients with this lethal form of cancer.
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